Section II. Targets for anaemia treatment

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 2, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; ETHNIC GROUP; HEMATOCRIT; HEMOCONCENTRATION; HEMODIALYSIS; HUMAN; LUNG DISEASE; NEGRO; PATIENT CARE; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SICKLE CELL ANEMIA; SURVIVAL; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ACCESS;

EID: 2942702034     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1025     Document Type: Article

References (105)

1. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300: 573-578
2. Keown PA. Quality of life in end-stage renal disease patients during recombinant erythropoietin therapy. The Canadian erythropoietin study. Contrib Nephrol 1991; 88: 81-86
3. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60: 390-396
4. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000; 15: 23-28
5. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
6. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
7. Möcks J, Franke W. Ehmer B et al. Analysis of safety database for long term epoetin beta treatment. A meta analysis covering 3697 patients. In: Koch KM, Stein G, eds. Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. Marcel Dekker, New York, 1997; 163-179
8. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
9. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int 2002; 61 [Suppl 80]: S44-S48
10. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy dialysis registry. Nephrol Dial Transplant 1998; 13: 1642-1644
11. Locatelli F, Pisoni RL, Combe C et al. Anaemia in five European countries and associated morbidity and mortality among haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
12. Strippoli GF, Manno C, Schena FP, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease (Cochrane review). Cochrane Database Syst Rev 2003; 1: CD003967
13. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989; 110: 108-114
14. Kleinman KS, Schweitzer SU, Perdue ST et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989; 14: 486 495
15. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927-936
16. Watson AJ, Gimenez LF, Cotton S et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89: 432-435
17. Teehan BP, Benz RL, Sigler MH, Brown JM. Early intervention with recombinant human erythropoietin therapy. Semin Nephrol 1990; 10: 28-34
18. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554
19. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185
20. Morris KP, Sharp J, Watson S, Coulthard MG. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 1993; 69: 580-586
21. Sikole A, Polenakovic M, Spirovska V et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-984
22. Bahlmann J, Schöter KH, Scigalla P et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 1991; 88: 90-106
23. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
24. Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 1999; 13: 143 147
25. Furuland H, Linde T, Ahlmén J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 28: 353-361
26. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Update Software, Oxford
27. Amann K, Ritz E. The heart in renal failure: morphological changes of the myocardium - new insights. J Clin Basic Cardiol 2001; 4: 109-113
28. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999; 14: 29-36
29. Eckardt KU. Anemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001; 16: 2-8
30. Cannella G, La Canna G, Sandrini M et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272-278
31. Macdougall IC, Lewis NP, Saunders MJ et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin Lancet 1990; 335: 489-493
32. Low-Friedrich I, Grutzmacher P, Marz W et al. Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 1990; 8: 272-278
33. Silberberg J, Racine N, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
34. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
35. Fellner SK, Lang RM, Neumann A et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315
36. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
37. Lim PS, Yeh CH, Hung TS. Effects of recombinant erythropoietin on echocardiographic findings in elderly dialysis patients. Nephrology 1997; 3: 149-154
38. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effects of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
39. Portoles J, Torralbo A, Martin P et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study Clin Nephrol 1991; 35: 280-287
40. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in, and survival of patients receiving hemodialysis: follow-up of an interventional study J Am Soc Nephrol 2001; 12: 2759-2767
41. Wizemann V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy Nephron 1993; 64: 202-206
42. McMahon LP. Advances in anaemia management: current evidence. Nephrology 2002; 7: 257-261
43. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-146
44. Muirhead N, Bargman J, Burgess E et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26 [2 Suppl 1]: S1-S24
45. Mayer G, Thum J, Cada EM et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525-528
46. Wolcott DL, Marsh JT, La Rue A et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478-485
47. Robertson HT, Haley NR, Guthrie M et al. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 1990; 15: 325-332
48. Schaefer RM, Kokot F, Heidland A. Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 1989; 76: 273-281; discussion 281-282
49. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991; 58: 129-134
50. Sagales T, Gimeno V, Planella MJ et al. Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure. Kidney Int 1993; 44: 1109-1115
51. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14: 14-18
52. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263: 825-830
53. Auer J, Simon G, Stevens J et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 1992; 12: 40-42
54. Moreno F, Aracil FJ, Perez R, Valderrábano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27: 548-556
55. Brown WS, Marsh JT, Walcott D et al. Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients. Neuropsychologia 1991; 29: 35-45
56. Grimm G, Stockenhuber F, Schneeweiss B et al. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990; 38: 480-486.
57. Marsh JT, Brown WS, Woolcott D et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155-163
58. Beuerstein KM, Nissenson AR, Port FK et al. The effects of recombinant human erythropoietin on functional health and well-being of chronic dialysis patients J Am Soc Nephrol 1996; 7: 763-773
59. Eschbach JW, Glenny R, Robertson T et al. Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe [abstract]. J Am Soc Nephrol 1993; 4: 425
60. Suzuki M, Tsutsui M, Yokoyama A, Hirasawa Y. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Artif Organs 1995; 19: 1258-1261
61. Pickett JL, Theberge DC, Brown WS et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33: 1122-1130
62. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-342
63. Painter P, Moore G, Carlson L et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life Am J Kidney Dis 2002; 39: 257-265
64. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-1316
65. Paulitschke M, Ludat K, Riedel E, Hampl H. Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits. Clin Nephrol 2000; 53 [1 Suppl]: S36-S41
66. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 1999; 56: 253-260
67. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Renal Fail 2000; 22: 435-444
68. Roth D, Smith RD, Schulman G et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784
69. Jungers P, Khoa TN, Joly D et al. Atherosclerotic complications in chronic renal failure: epidemiology and predictive factors. Adv Nephrol Necker Hosp 2000; 30: 177-199
70. Linde T, Ekberg H, Forslund T et al. The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. Transplantation 2001; 71: 79-82
71. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304
72. Movilli E, Pertica N, Camerini C et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 2002; 39: 850-853
73. Duchesne-Gueguen M, Durand F, Le Pogamp P et al. Study of haemorheological parameters in patients with chronic renal failure and evolution of those parameters in the course of dialysis treatment. Clin Haemrheol 1988; 8: 407-414
74. Canaud B, Donadieu P, Polito C et al. Erythropoietin-associated hypertension: what role for blood viscosity changes? Nephron 1989; 51: 430-431
75. Wakeen M, Zimmerman SW. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998; 32: 488-493
76. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990; 323: 366-72
77. Galan P, Hercberg S, Soustre Y, Dop MC, Dupin H. Factors affecting iron stores in French female students. Hum Nutr Clin Nutr 1985; 39: 279-287
78. Puolakka J. Serum ferritin in the evaluation of iron status in young healthy women. Acta Obstet Gynecol Scand Suppl 1980; 95: 35-41
79. Cavill I. Iron status as measured by serum ferritin: the marker and its limitations. Am J Kidney Dis 1999; 34: S12-S17
80. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93-130
81. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
82. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191-196
83. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 1991; 14: 271-276
84. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-88
85. Kooistra MP, Marx JJ. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 2578-2582
86. Deira J, Martin M, Sanchez S, Garrido J, Nunez J, Tabernero JM. Evaluation of intestinal iron absorption by indirect methods in patients on hemodialysis receiving oral iron and recombinant human erythropoietin. Am J Kidney Dis 2002; 39: 594-599
87. Lindsay RM, Burton JA, Edward N, Dargie HJ, Prentice CR, Kennedy AC. Dialyzer blood loss. Clin Nephrol 1973; 1: 29-34
88. Longnecker RE, Goffinet JA, Hendler ED. Blood loss during maintenance hemodialysis Trans Am Soc Artif Intern Organs 1974; 20: 135-141
89. Milman N. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol 1996; 63: 103-135
90. MacPhail AP, Derman DP, Bothwell TH et al. Serum ferritin concentrations in black miners. S Afr Med J 1979; 55: 758-760
91. Beutler F, Barton JC, Felitti VJ et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305-309
92. Waalen J, Felitti, V, Beutler, E. Haemoglobin and ferritin concentrations in men and women: cross sectional study. BMJ 2002; 325: 137
93. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510
94. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002; 99: 1489-1491
95. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
96. Gokal R, Millard PR, Weatherall DJ, Callender ST, Ledingham JG, Oliver DO. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 1979; 48: 369-391
97. Hakim RM, Stivelman JC, Schulman G et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293-299
98. Schaefer RM, Kokot F, Heidland A. Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 1989; 76: 273-281; discussion 281-282
99. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989; 36: 1125-1132
100. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699
101. Hershko C, Peto TEA, Weatherall DJ. Iron and infection. BMJ 1988; 296: 660-664
102. Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994; 21: 16-20
103. Lazarus JM, Hakim RM, Newell J. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 1990; 16: 101-108
104. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504-507
105. Collins A, Ebben J, Ma J, Xia H. Iron dosing patterns and mortality. J Am Soc Nephrol 1998; 9: 205A